Sangamo Therapeutics, Inc.

Good afternoon, and welcome to the Sangamo Therapeutics second quarter 2024 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Patricia Durrababu, Chief Financial Officer, Natalie Dubastring-Fellow, Chief Development Officer, Amy Pooler, Head of Research, and Greg Davis, Head of Technology. Slides from our corporate presentation can be found on our website, sangamo.com, under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to Sangamo's cash runway, plans to obtain additional capital and ability to continue to operate as a going concern, the therapeutic and commercial potential of Sangamo's product candidates and technologies, Sangamo's ability to earn and receive payments from its collaboration and license agreements, including the Genentech and Pfizer agreements, Pfizer's, sorry, Sangamo's expectations regarding new collaboration and license agreements, the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and regulatory submissions, upcoming catalysts and milestones, and other statements that are not historical facts. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings of the SEC, specifically on our annual report on Form 10-K for the fiscal year ended December 31, 2023, as supplemented by Sangamo's quarterly reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024. and subsequent filings and reports that Sangamo makes from time to time with the SEC. The forward-looking statements stated today are made as of today, and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Sandy McRae.

Thank you, Louise, and good afternoon to everyone joining the call today. This has been such an exciting and important quarter for Sangamo. At our last earnings call, we shared compelling preclinical data demonstrating the potential of our neurology epigenetic regulators, AAV capsid delivery platform, and next generation genome engineering platform. Importantly, we also outlined our resolute focus on raising additional capital in order to progress these compelling assets into the clinic and to boards patients in need. To that end, this morning, we were thrilled to announce our first neurology epigenetic regulator and delivery capsid license agreement. This comes close on the heels of the highly compelling phase three affine data for the haemophilia A gene therapy we are co-developing with Pfizer. Both announcements demonstrate external interest in and validation of the potential of our science, and both could meaningfully extend our cash runway as we continue to advance our wholly owned neurology epigenetic regulation pipeline. Getting into the details of our STAC BBB capsid deal, this morning we announced a license agreement with Genentech to develop novel intravenously administered genomic medicines for neurodegenerative disease. We have granted Genentech an exclusive license to our highly potent zinc finger repressors that are targeted to tau, a critical gene involved in Alzheimer's disease and other tauopathies, as well as an additional undisclosed second neurology target. For these same targets, we've also granted Genentech an exclusive license to our industry-leading neurotropic delivery capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and brain transduction in non-human primates. As we have shared before, we strongly believe that our powerful combination of proprietary genome targeting cargo paired with our neurotropic delivery capsid platform is critical to the successful development of neurology-focused genomic medicines. We believe this agreement with Genentech, a leader in the biotechnology and neurology space, reinforces this potent combination and underscores how Sangamo is able to provide both. We are delighted that Genentech chose our zinc finger and capsid delivery technologies to address their neurology needs. We expect to receive from Genentech $50 million in near-term upfront license fees and milestone payments, which we anticipate will extend our cash runway into early 2025 and are eligible to earn up to $1.9 billion in development and commercial milestone payments, as well as tiered royalties or net sales of such products under the agreement. Our agreement with Genentech is significant as we believe it paves the way for others in the future. We anticipate this agreement could be the first of multiple capsid collaborations as we have ongoing discussions with other interested parties alongside our Fabry partnership discussions. Generating additional funding continues to be our top priority as we work to position Sangamo for long-term success and value creation, and are hopeful to have news of additional transactions in the second half of this year. I would now like to hand over to Natalie, our Head of Development, who will share details on the positive top-line phase three fine trial results and take us through other pipeline updates. Natalie.